Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 20/20 | 0.68 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.55 |
| ▸ | CASP3 | P42574 | 1/20 | 0.52 |
| ▸ | CASP6 | P55212 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4386803 | 1.00 | ADRB2 (0.68) | ADRB2ADRA1DCASP3CASP6 | |
| SCHEMBL4384748 | 0.95 | ADRB2 (0.66) | ADRB2ADRA1DCASP3CASP6 | |
| SCHEMBL4384742 | 0.95 | ADRB2 (0.66) | ADRB2ADRA1DCASP3CASP6 | |
| SCHEMBL4390059 | 0.93 | ADRB2 (0.61) | ADRB2ADRA1D | |
| SCHEMBL4390066 | 0.93 | ADRB2 (0.61) | ADRB2ADRA1D | |
| SCHEMBL4393016 | 0.92 | ADRB2 (0.77) | ADRB2CASP3CASP6 | |
| SCHEMBL4393023 | 0.92 | ADRB2 (0.77) | ADRB2CASP3CASP6 | |
| SCHEMBL4253627 | 0.88 | ADRB2 (0.85) | ADRB2ADRA1D | |
| SCHEMBL4253631 | 0.88 | ADRB2 (0.85) | ADRB2ADRA1D | |
| SCHEMBL4384910 | 0.87 | ADRB2 (0.67) | ADRB2CASP3CASP6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1577291-A1 | Phenylethanolamine derivatives as beta-2 agonists | Pfizer Limited (GB) | 2005-09-21 | — | — | EP | claimed |
| US-7629358-B2 | Compounds useful for the treatment of diseases | PFIZER INC (US) | 2009-12-08 | — | — | US | disclosed |
| US-20050234097-A1 | Compounds useful for the treatment of diseases | PFIZER INC | 2005-10-20 | — | — | US | disclosed |
| EP-1577291-A1 | Phenylethanolamine derivatives as beta-2 agonists | Pfizer Limited (GB) | 2005-09-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234097-A1 | Compounds useful for the treatment of diseases | LTC4S, CYP11B2, CYP11B1 | ADRB2 731/4885ADRA1D 1054/4885CASP3 2450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.